siRNA intervention inhibiting viral replication and delivery strategies for treating herpes simplex viral infection

Vyshnavi Manda, Venkata Rao Josyula, Raghu Chandrashekar Hariharapura

Research output: Contribution to journalComment/debate

Abstract

The effective treatment of herpes simplex virus (HSV) infections generally involves the use of antiviral nucleoside drugs, but with increasing reports of antiviral resistance, the use of these drugs is challenged. Hence, a need arises to explore alternate treatment options. In this review we have discussed various targets that have been explored to control the HSV replication using siRNA therapeutics. We have also discussed the advantages of targeting a less explored UL10 gene to develop an alternate therapeutic intervention. Gene silencing can induce an inhibitory activity to virus spread and infection. The capacity and suitability of UL10 gene as siRNA induced silencing target in eliciting the desired antiviral effect in patients is identified and particularly discussed. The major challenge associated with the siRNA therapeutics is their delivery. The various viable delivery options, that are being explored in the recent times is summarized and different delivery pathways and strategies are reviewed as a part of the study.

Original languageEnglish
Pages (from-to)180-185
Number of pages6
JournalVirusDisease
Volume30
Issue number2
DOIs
Publication statusPublished - 01-06-2019

Fingerprint

Herpes Simplex
Virus Diseases
Small Interfering RNA
Simplexvirus
Antiviral Agents
Viral Drug Resistance
Therapeutics
Gene Silencing
Virus Replication
Nucleosides
Genes

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases

Cite this

@article{0f2a744f98de446a8b8cc538e4a4b035,
title = "siRNA intervention inhibiting viral replication and delivery strategies for treating herpes simplex viral infection",
abstract = "The effective treatment of herpes simplex virus (HSV) infections generally involves the use of antiviral nucleoside drugs, but with increasing reports of antiviral resistance, the use of these drugs is challenged. Hence, a need arises to explore alternate treatment options. In this review we have discussed various targets that have been explored to control the HSV replication using siRNA therapeutics. We have also discussed the advantages of targeting a less explored UL10 gene to develop an alternate therapeutic intervention. Gene silencing can induce an inhibitory activity to virus spread and infection. The capacity and suitability of UL10 gene as siRNA induced silencing target in eliciting the desired antiviral effect in patients is identified and particularly discussed. The major challenge associated with the siRNA therapeutics is their delivery. The various viable delivery options, that are being explored in the recent times is summarized and different delivery pathways and strategies are reviewed as a part of the study.",
author = "Vyshnavi Manda and Josyula, {Venkata Rao} and Hariharapura, {Raghu Chandrashekar}",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s13337-018-00508-z",
language = "English",
volume = "30",
pages = "180--185",
journal = "VirusDisease",
issn = "2347-3584",
publisher = "Springer India",
number = "2",

}

siRNA intervention inhibiting viral replication and delivery strategies for treating herpes simplex viral infection. / Manda, Vyshnavi; Josyula, Venkata Rao; Hariharapura, Raghu Chandrashekar.

In: VirusDisease, Vol. 30, No. 2, 01.06.2019, p. 180-185.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - siRNA intervention inhibiting viral replication and delivery strategies for treating herpes simplex viral infection

AU - Manda, Vyshnavi

AU - Josyula, Venkata Rao

AU - Hariharapura, Raghu Chandrashekar

PY - 2019/6/1

Y1 - 2019/6/1

N2 - The effective treatment of herpes simplex virus (HSV) infections generally involves the use of antiviral nucleoside drugs, but with increasing reports of antiviral resistance, the use of these drugs is challenged. Hence, a need arises to explore alternate treatment options. In this review we have discussed various targets that have been explored to control the HSV replication using siRNA therapeutics. We have also discussed the advantages of targeting a less explored UL10 gene to develop an alternate therapeutic intervention. Gene silencing can induce an inhibitory activity to virus spread and infection. The capacity and suitability of UL10 gene as siRNA induced silencing target in eliciting the desired antiviral effect in patients is identified and particularly discussed. The major challenge associated with the siRNA therapeutics is their delivery. The various viable delivery options, that are being explored in the recent times is summarized and different delivery pathways and strategies are reviewed as a part of the study.

AB - The effective treatment of herpes simplex virus (HSV) infections generally involves the use of antiviral nucleoside drugs, but with increasing reports of antiviral resistance, the use of these drugs is challenged. Hence, a need arises to explore alternate treatment options. In this review we have discussed various targets that have been explored to control the HSV replication using siRNA therapeutics. We have also discussed the advantages of targeting a less explored UL10 gene to develop an alternate therapeutic intervention. Gene silencing can induce an inhibitory activity to virus spread and infection. The capacity and suitability of UL10 gene as siRNA induced silencing target in eliciting the desired antiviral effect in patients is identified and particularly discussed. The major challenge associated with the siRNA therapeutics is their delivery. The various viable delivery options, that are being explored in the recent times is summarized and different delivery pathways and strategies are reviewed as a part of the study.

UR - http://www.scopus.com/inward/record.url?scp=85060621563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060621563&partnerID=8YFLogxK

U2 - 10.1007/s13337-018-00508-z

DO - 10.1007/s13337-018-00508-z

M3 - Comment/debate

VL - 30

SP - 180

EP - 185

JO - VirusDisease

JF - VirusDisease

SN - 2347-3584

IS - 2

ER -